Rodman & Renshaw weighs in on Curis (CRIS +4.7%) following its unveiling of an agreement...


Rodman & Renshaw weighs in on Curis (CRIS +4.7%) following its unveiling of an agreement with the Leukemia & Lymphoma Society. Analysts with the firm say that funding from the organization will support the development of CUDC-907, as well as add value to early stage pipeline.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs